XPD polymorphism and risk of subsequent cancer in individuals with nonmelanoma skin cancer

被引:0
|
作者
Brewster, AM
Alberg, AJ
Strickland, PT
Hoffman, SC
Helzlsouer, K
机构
[1] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Individuals with nonmelanoma skin cancer (NMSC) are at increased risk of developing subsequent cancers. Genetic predisposition to reduced DNA repair capacity may be an underlying susceptibility factor explaining the excess risk of malignancies. To test this hypothesis, a cohort study was conducted to examine the association between XPD Lys751Gln polymorphism and risk of a second primary cancer in individuals with NMSC. Methods: A subgroup of 481 individuals with a history of NMSC who participated in the CLUE II community-based cohort was followed for the development of a second primary cancer. Blood specimens donated in 1989 were genotyped for the XPD Lys751Gln polymorphism using the 5' nuclease assay. Cox proportional regression with delayed entry was used to calculate the incidence rate ratio (IRR) and 95% confidence interval (95% CD for risk of developing a second primary cancer according to XPD genotype. All statistical tests were two sided. Results: Eighty individuals developed a second primary cancer. The most frequent occurring cancers were of the prostate (18%), lung (15%), and breast (15%). Persons with at least one Gin allele had an increased risk of a second primary cancer compared with the reference Lys/Lys genotype (adjusted IRR 2.22, 95% CI 1.30-3.76). When the reference category was limited to never smokers with the Lys/Lys genotype, the risk of developing a second primary cancer associated with having at least one Gin allele was increased >3-fold in both never smokers (IRR 3.93, 95% CI 1.36-11.36) and ever smokers (IRR 6.14, 95% Cl 2.17-17.37). Conclusion: These findings suggest that individuals with NMSC who have the variant XPD Gin allele are at increased risk of developing a second primary cancer.
引用
收藏
页码:1271 / 1275
页数:5
相关论文
共 50 条
  • [1] Nonmelanoma skin cancer and risk for subsequent malignancy
    Chen, Jiping
    Ruczinski, Ingo
    Jorgensen, Timothy J.
    Yenokyan, Gayane
    Yao, Yin
    Alani, Rhoda
    Liegeois, Nanette J.
    Hoffman, Sandra C.
    Hoffman-Bolton, Judith
    Strickland, Paul T.
    Helzlsouer, Kathy J.
    Alberg, Anthony J.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (17): : 1215 - 1222
  • [2] Re: Nonmelanoma Skin Cancer and Risk for Subsequent Malignancy
    Grant, William B.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (03): : 210 - 210
  • [3] Response: Re: Nonmelanoma Skin Cancer and Risk for Subsequent Malignancy
    Alberg, Anthony J.
    Chen, Jiping
    Ruczinski, Ingo
    Jorgensen, Timothy J.
    Alani, Rhoda
    Liegeois, Nanette J.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (03) : 210 - 211
  • [4] PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer
    Asplund, A
    Gustafsson, AC
    Wikonkal, NM
    Sela, A
    Leffell, DJ
    Kidd, K
    Lundeberg, J
    Brash, DE
    Pontén, F
    BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (05) : 868 - 873
  • [5] Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer - A critical review of the literature and meta-analysis
    Marcil, I
    Stern, RS
    ARCHIVES OF DERMATOLOGY, 2000, 136 (12) : 1524 - 1530
  • [6] Cancer risk after nonmelanoma skin cancer
    Bonn, D
    LANCET, 1998, 352 (9131): : 885 - 885
  • [7] Subsequent Nonmelanoma Skin Cancer after Liver Transplantation
    Herrero, J. I.
    Espana, A.
    D'Avola, D.
    Pardo, F.
    Inarrairaegui, M.
    Rotellar, F.
    Sangro, B.
    Quiroga, J.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (06) : 1568 - 1570
  • [8] Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of squamous cell carcinoma
    Kemmett, D
    Chan, C
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 : 30 - 31
  • [9] Risk of Nonmelanoma Skin Cancer with Azathioprine Use
    Maddox, Jessica S.
    Soltani, Keyoumars
    INFLAMMATORY BOWEL DISEASES, 2008, 14 (10) : 1425 - 1431
  • [10] Nonmelanoma Skin Cancer
    Brandt, Michael G.
    Moore, Corey C.
    FACIAL PLASTIC SURGERY CLINICS OF NORTH AMERICA, 2019, 27 (01) : 1 - +